Chad Robins Sells 83,332 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 83,332 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the sale, the chief executive officer directly owned 2,217,781 shares of the company’s stock, valued at $31,958,224.21. This represents a 3.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 9.7%

Shares of ADPT opened at $13.40 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $6.77 and a 12-month high of $20.76. The firm has a 50-day moving average price of $15.07 and a 200 day moving average price of $15.96. The firm has a market capitalization of $2.06 billion, a P/E ratio of -33.50 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 51.0% on a year-over-year basis. Equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Allianz Asset Management GmbH lifted its position in shares of Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after purchasing an additional 242,474 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Adaptive Biotechnologies by 82.5% during the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock worth $1,019,000 after purchasing an additional 30,785 shares in the last quarter. Affinity Wealth Management LLC acquired a new stake in shares of Adaptive Biotechnologies during the third quarter worth about $4,541,000. Aristotle Atlantic Partners LLC lifted its position in shares of Adaptive Biotechnologies by 8.6% during the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after purchasing an additional 247,402 shares in the last quarter. Finally, Huntleigh Advisors Inc. acquired a new stake in shares of Adaptive Biotechnologies during the third quarter worth about $1,227,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent coverage highlights a sharp intraday rally driven by the company’s recent quarter-to-quarter momentum — revenue and EPS beats and strong year‑over‑year sales growth were cited as the core catalyst. Why Adaptive Biotechnologies Corporation’s (ADPT) Stock Is Up 10.28%
• Positive Sentiment: Coverage from The Motley Fool emphasizes a ~55% year‑over‑year revenue jump in the latest quarter, reinforcing the growth narrative that has drawn buyer interest; the article also flags items for investors to monitor (guidance, margins, product adoption). Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%
• Positive Sentiment: Wall Street sentiment is broadly constructive: several firms have reiterated buy/overweight ratings and lifted price targets, supporting the bullish case on ADPT’s growth trajectory. MarketBeat ADPT Overview
• Neutral Sentiment: Executives say many of the recent insider sales were executed under pre‑arranged Rule 10b5‑1 plans; that reduces the likelihood of opportunistic timing but still results in incremental share supply hitting the market. SEC Form 4 (Example)
• Negative Sentiment: Large insider selling by senior management is the primary near‑term negative: CEO Chad Robins sold substantial blocks in early April (~120k shares across filings) and COO Julie Rubinstein sold multiple blocks (totaling many tens of thousands of shares), reducing each executive’s direct holdings by a few percent and adding downward pressure on the stock. CEO Form 4 COO Form 4 InsiderTrades Summary

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.